Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering talks about the role of PARP inhibitors in the treatment of small cell lung cancer. February 2014.

[powerpress]

Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

[powerpress]

Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.

[powerpress]